Biotechnology News and Research

RSS

Small biotechnology companies fail to attact new capital, BIO conveyes support for Investment Act of 2009

Small biotechnology companies developing new medical therapies and advanced biofuels need help attracting new capital, as investors have become especially risk averse. The Biotechnology Industry Organization (BIO) today conveyed support for the Small Business Early-Stage Investment Act of 2009, which would create a funding program at the Small Business Administration to stimulate growth in early-stage technology-based companies.

15 Oct 2009

Specific immune system cells linked to susceptibility of younger people to variant CJD

Specific cells within the immune system could help explain why younger people are more susceptible to variant CJD, scientists believe.

15 Oct 2009

pSivida achieves milestone in Phase III Iluvien trial, last patient completes two-year follow up visit

pSivida Corp., a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today announced that the last patient in the Phase III clinical trial being conducted by its collaborative partner, Alimera Sciences, for a new treatment for diabetic macular edema (DME) has completed the two-year follow up visit.

15 Oct 2009

Genzyme ranked third on the global list for best employers

Genzyme Corporation announced today that scientists have again named the company a top employer in a survey ranking the reputations of biotechnology and pharmaceutical companies. Genzyme is ranked third on the global list of 575 companies, the second consecutive year it has achieved this position. Genzyme placed among the top 10 of all biotechnology and pharmaceutical companies in the world for the seventh year in a row.

15 Oct 2009

BioMedReports.Com releases an exclusive interview with spokesman for Biomagnetics Diagnostics

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has released an exclusive interview with a spokesman for Biomagnetics Diagnostics Corp., the company behind a revolutionary diagnostic systems and technology for malaria, tuberculosis, HIV and hepatitis field testing.

15 Oct 2009

Lonza and Patheon extend exclusivity period; explore transaction options

Lonza Group AG ("Lonza") and the Special Committee of Independent Directors of Patheon Inc. ("Patheon" or the "Company") (TSX:PTI) today announced the extension of the exclusivity period granted to Lonza by Patheon, which had been scheduled to expire today

15 Oct 2009

MMR Information Systems, Unis-Tonghe Technology ink Memorandum of Understanding

MMR Information Systems, Inc. and Unis-Tonghe Technology (Zhengzhou) Co., Ltd., announced today that the companies have entered into a Memorandum of Understanding ("MOU") and plan to sign a Master Agreement by December 15, 2009.

15 Oct 2009

Cobroxin OTC pain reliever is now available online

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its over-the-counter pain reliever, Cobroxin, is available for sale online at Cobroxin.com.

15 Oct 2009

Evonik Industries to acquire Tippecanoe Laboratories from Eli Lilly

Eli Lilly and Company today announced the sale of its Tippecanoe Laboratories manufacturing facility to Evonik Industries AG, one of the world's largest chemical companies.

15 Oct 2009

NIH grants Affymetrix $24.8M for genotyping project

Affymetrix, Inc. today announced that the Kaiser Permanente Research Program on Genes, Environment, and Health (RPGEH) and the University of California at San Francisco (UCSF) have entered into an agreement with Affymetrix to support genome-wide analyses of DNA samples from 100,000 Kaiser Permanente members.

15 Oct 2009

Illumina and Solexa deny patent infringement allegations

Illumina, Inc. today announced that, together with Solexa its wholly owned subsidiary, it has filed its initial response to the lawsuit brought by Life Technologies and Applied Biosystems on September 21, 2009 in U.S. District Court in Wilmington, Delaware. In their answer, Illumina and Solexa have denied all of Life’s and AB’s allegations of patent infringement, and have asserted that AB’s licensed patents are invalid.

From Illumina, Inc. 15 Oct 2009

PharmaTelevision teams up with EBD Group to offer Television Interview and Media Training

PharmaTelevision(R), the authoritative channel for the pharmaceutical, biotechnology and related industries, today announced that it is teaming up with the EBD Group to offer delegates at BIO-Europe a Television Interview and Media Training.

15 Oct 2009

Commonwealth Biotechnologies to acquire GL Biochem

Commonwealth Biotechnologies, Inc. has recently announced a definitive share purchase agreement to acquire Shanghai-based GL Biochem and associated businesses (the “GL Group”), the largest global supplier of research-grade peptide products and peptide reagents.

15 Oct 2009

Eden Biodesign to manufacture Biotecnol's Cardiotrophin-1

Eden Biodesign, a globally-integrated provider of biopharmaceutical process development, cGMP manufacturing and consultancy services, today announced it has been selected by Biotecnol SA to manufacture Cardiotrophin-1 for potential use in certain liver indications.

15 Oct 2009

Postive vote from FDA Advisory Committee for Fampridine-SR 10

Acorda Therapeutics, Inc. today announced the U.S. Food and Drug Administration (FDA) Peripheral and Central Nervous System Drugs (PCNSD) Advisory Committee voted 12 to 1 that clinical data on Fampridine-SR 10 mg twice daily demonstrated substantial evidence of effectiveness as a treatment to improve walking in people with multiple sclerosis (MS) and voted 10 to 2 (1 abstention) that it is clinically meaningful and can be safe for use.

15 Oct 2009

FDA approves ZyStor Therapeutics' ZC-701 for Phase I human safety trial

ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, today announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment of Pompe disease.

14 Oct 2009

EMEA grants ArQule's ARQ 197 orphan drug designation

ArQule, Inc. today announced that the European Medicines Evaluation Agency (EMEA) has designated ARQ 197 as an orphan medical product for the treatment of soft tissue sarcoma.

14 Oct 2009

Medtronic announces results of study comparing INFUSE Bone Graft to autogenous bone graft

Medtronic, Inc. today announced results of a study comparing the safety and effectiveness of INFUSE® Bone Graft to autogenous bone graft (bone harvested from the patient) when used in maxillary sinus floor augmentation.

14 Oct 2009

Delegation from All-CABPA visits Sundia

A delegation from the Alliance of Chinese-American Biotechnology and Pharmaceutical Associations (All-CABPA) visited Sundia in Shanghai's famous Zhangjiang Hi-Tech Park on October 12.

14 Oct 2009

Roche and Genentech to discuss their radical collaborative business model at the Windhover Conference

Elsevier Business Intelligence and Windhover Conferences have announced a major addition to the lineup for their upcoming Therapeutic Area Partnerships event, Nov. 17-19 in Boston, MA. In Roche and Genentech: Understanding Their Collaborative Business Development Model, the two executives who designed and implemented the radical new collaborative business model will share exactly how they make this relationship work and the outlook for the business model in the future.

14 Oct 2009